Findings of Sodium-Glucose Cotransporter-2 Inhibitor Kidney Outcome Trials Applied to a Canadian Chronic Kidney Disease Population: A Retrospective Cohort Study
Sign Up to like & getrecommendations! Published in 2022 at "Canadian Journal of Kidney Health and Disease"
DOI: 10.1177/20543581221145068
Abstract: Background: The canagliflozin and renal endpoints in diabetes with established nephropathy clinical evaluation (CREDENCE) and dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trials have demonstrated significant kidney benefits with sodium-glucose cotransporter-2… read more here.
Keywords: british columbia; disease; kidney; credence ... See more keywords